1. Pharmacological Treatment for Social Cognition: Current Evidence
- Author
-
Claudio Brasso, Cristiana Montemagni, Elisa Del Favero, Silvio Bellino, Cecilia Riccardi, and Paola Rocca
- Subjects
Social Cognition ,QH301-705.5 ,medicine.medical_treatment ,Review ,Catalysis ,Pharmacological treatment ,Inorganic Chemistry ,03 medical and health sciences ,0302 clinical medicine ,Cognition ,pharmacological treatment ,Social cognition ,medicine ,Animals ,Humans ,In patient ,Physical and Theoretical Chemistry ,Biology (General) ,Cognitive impairment ,Antipsychotic ,Molecular Biology ,QD1-999 ,Spectroscopy ,Standard treatment ,Organic Chemistry ,Schizophrenia ,Antipsychotic Agents ,General Medicine ,medicine.disease ,030227 psychiatry ,Computer Science Applications ,antipsychotic ,schizophrenia ,Chemistry ,Psychology ,030217 neurology & neurosurgery ,Clinical psychology - Abstract
Cognitive impairment is currently considered a core feature of schizophrenia (SZ) and is gaining attention as a fundamental therapeutic target. Standard treatment for SZ involves the use of antipsychotics that are successfully used to control positive symptoms and disorganized behaviour. However, it is still unclear whether they are effective on social cognition (SC) impairment. Furthermore, different medications are currently being studied to improve SC in patients with SZ. A literature search on this topic was conducted using the PubMed database. All kinds of publications (i.e., reviews, original contributions and case reports) written in English and published in the last 15 years were included. The aim of our literature review is to draw a picture of the current state of the pharmacological treatment of SC impairment in SZ.
- Published
- 2021